NCT02414503View on ClinicalTrials.gov

Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Autism Spectrum Disorder
Interventions
DRUG

8IU intranasal oxytocin

DRUG

24IU intranasal oxytocin

DRUG

Placebo

DEVICE

OptiNose Breath Powered Bi

Trial Locations (1)

0424

NORMENT, KG Jebsen Centre for Psychosis Research - TOP Study, Oslo

Sponsors

Lead Sponsor

OptiNose AS
All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

University of Oslo

OTHER

lead

OptiNose AS

INDUSTRY